{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T08:10:02Z","timestamp":1762762202075,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006393","name":"Universidad de Granada","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006393","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Stereotactic body radiotherapy (SBRT) has become an excellent non-invasive alternative for many patients with primary renal cell carcinoma (RCC) and adrenal malignancies (AM). The aims of this study were to analyse how tumor-, patient- and treatment-related factors may influence the outcomes and side effects of SBRT and to assess its benefits as an alternative to surgery.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective, multicenter study included 25 lesions in 23 patients treated with SBRT using different devices (LINAC, CyberKnife<jats:sup>\u00ae<\/jats:sup> and Tomotherapy<jats:sup>\u00ae<\/jats:sup>). A multivariate linear regression was used for the statistical study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Local control time was higher than six months in more than 87% of patients and treatment response was complete for 73.68%. There was an overall 2-year survival of 40% and none of the deaths were secondary to renal or adrenal local progression. Patients treated with lower total radiation dose (mean [m]\u2009=\u200955\u00a0Gy) but less fractions with more dose per fraction (&gt;\u20098.5\u00a0Gy) showed better outcome. Patients with previous chemotherapy and surgery treatments also showed higher complete response and disease-free survival (&gt;\u20096 months).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study highlights the importance of ultra-hypofractionated regimens with higher doses per session. Thus, the referral of patients with RCC and AM to Radiotherapy and Oncology departments should be encouraged supporting the role of SBRT as a minimally invasive and outpatient treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00345-024-05140-9","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T12:05:30Z","timestamp":1721822730000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Stereotactic Body Radiotherapy: is less fractionation more effective in adrenal and renal malignant lesions?"],"prefix":"10.1007","volume":"42","author":[{"given":"Daniel","family":"Rivas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"de la Torre-Luque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Moreno-Olmedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paloma","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Su\u00e1rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Serradilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregorio","family":"Arregui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morena","family":"Sallabanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Lazo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8159-7969","authenticated-orcid":false,"given":"Mar\u00eda Isabel","family":"N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Escarlata","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"key":"5140_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.14740\/wjon1279","volume":"11","author":"SA Padala","year":"2020","unstructured":"Padala SA, Barsouk A, Thandra KC et al (2020) Epidemiology of renal cell carcinoma. World J Oncol 11:79\u201387. https:\/\/doi.org\/10.14740\/wjon1279","journal-title":"World J Oncol"},{"key":"5140_CR2","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s10585-021-10124-9","volume":"38","author":"C Franzese","year":"2021","unstructured":"Franzese C, Nicosia L, Facondo G et al (2021) Stereotactic body radiation therapy for adrenal gland metastases: outcome and predictive factors from a multicenter analysis. Clin Exp Metastasis 38:511\u2013518. https:\/\/doi.org\/10.1007\/s10585-021-10124-9","journal-title":"Clin Exp Metastasis"},{"key":"5140_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A (2016) Cancer statistics. CA. Cancer J Clin 66:7\u201330. https:\/\/doi.org\/10.3322\/caac.21332","journal-title":"Cancer J Clin"},{"issue":"Suppl 2","key":"5140_CR4","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.21037\/cco.2017.06.30","volume":"6","author":"G Kothari","year":"2017","unstructured":"Kothari G, Louie AV, Pryor D et al (2017) Stereotactic body radiotherapy for primary renal cell carcinoma and adrenal metastases. Chin Clin Oncol 6(Suppl 2):S17. https:\/\/doi.org\/10.21037\/cco.2017.06.30","journal-title":"Chin Clin Oncol"},{"key":"5140_CR5","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.kjms.2015.09.007","volume":"31","author":"XW Pan","year":"2015","unstructured":"Pan XW, Cui XM, Huang H et al (2015) Radiofrequency ablation vs partial nephrectomy for treatment of renal masses: a systematic review and meta-analysis. Kaohsiung J Med Sci 31:649\u2013658. https:\/\/doi.org\/10.1016\/j.kjms.2015.09.007","journal-title":"Kaohsiung J Med Sci"},{"key":"5140_CR6","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1055\/s-2004-818511","volume":"47","author":"A Muacevic","year":"2004","unstructured":"Muacevic A, Kreth FW, Mack A, Tonn JC, Wowra B (2004) Stereotactic radiosurgery without radiation therapy providing high local tumor control of multiple brain metastases from renal cell carcinoma. Minim Invasive Neurosurg 47:203\u2013208. https:\/\/doi.org\/10.1055\/s-2004-818511","journal-title":"Minim Invasive Neurosurg"},{"key":"5140_CR7","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/S1470-2045(23)00513-2","volume":"25","author":"S Siva","year":"2024","unstructured":"Siva S, Louie AV, Kotecha R et al (2024) Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS). Lancet Oncol 25:e18\u2013e28. https:\/\/doi.org\/10.1016\/S1470-2045(23)00513-2","journal-title":"Lancet Oncol"},{"doi-asserted-by":"publisher","unstructured":"Ahmed KA, Barney BM, Macdonald OK et al (2013) Stereotactic body Radiotherapy in the treatment of adrenal metastases. Am J Clin Oncol 36. https:\/\/doi.org\/10.1097\/COC.0b013e3182569189.:509\u2009\u2013\u200913","key":"5140_CR8","DOI":"10.1097\/COC.0b013e3182569189"},{"unstructured":"Lemons JM, Blum JT (2020) Adrenal metastases (Carcinoma) Imaging. IOP Publishing Emedicine.com. https:\/\/emedicine.medscape.com\/article\/376585-overview. Accessed 20 March 2021","key":"5140_CR9"},{"key":"5140_CR10","doi-asserted-by":"publisher","first-page":"20200645","DOI":"10.1259\/bjr.20200645","volume":"93","author":"F Arcidiacono","year":"2020","unstructured":"Arcidiacono F, Aristei C, Marchionni A et al (2020) Stereotatic body radiotherapy for adrenal oligometastasis in lung cancer patients. Br J Radiol 93:20200645. https:\/\/doi.org\/10.1259\/bjr.20200645","journal-title":"Br J Radiol"},{"key":"5140_CR11","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.adro.2018.11.007","volume":"4","author":"ME Bernard","year":"2018","unstructured":"Bernard ME, Sutera PA, Iarrobino NA et al (2018) Initial results of prospective study of adjuvant pancreatic stereotactic body Radiation Therapy for Close or positive margins. Adv Radiat Oncol 4:294\u2013301. https:\/\/doi.org\/10.1016\/j.adro.2018.11.007eCollection 2019 Apr-Jun","journal-title":"Adv Radiat Oncol"},{"key":"5140_CR12","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13014-018-1040-z","volume":"13","author":"CM van Leeuwen","year":"2018","unstructured":"van Leeuwen CM, Oei AL, Crezee J et al (2018) The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies. Radiat Oncol 13:96. https:\/\/doi.org\/10.1186\/s13014-018-1040-z","journal-title":"Radiat Oncol"},{"unstructured":"National Institutes of Health. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 (2009) IOP Publishing Bethesda, MD: National Institutes of Health https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/Archive\/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf. Accessed 14 April 2021","key":"5140_CR13"},{"doi-asserted-by":"publisher","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026. :228\u2009\u2013\u200947","key":"5140_CR14","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"5140_CR15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ijrobp.2020.01.017","volume":"107","author":"WC Chen","year":"2020","unstructured":"Chen WC, Baal JD, Baal U et al (2020) Stereotactic body radiation therapy of adrenal metastases: a pooled meta-analysis and systematic review of 39 studies with 1006 patients. Int J Radiat Oncol Biol Phys 107:48\u201361. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.01.017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5140_CR16","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.adro.2020.01.002","volume":"5","author":"SR Grant","year":"2020","unstructured":"Grant SR, Lei X, Hess KR et al (2020) Stereotactic body Radiation Therapy for the definitive treatment of early-stage kidney Cancer: a survival comparison with surgery, tumor ablation, and Observation. Adv Radiat Oncol 5:495\u2013502. https:\/\/doi.org\/10.1016\/j.adro.2020.01.002","journal-title":"Adv Radiat Oncol"},{"key":"5140_CR17","doi-asserted-by":"publisher","first-page":"153303381882232","DOI":"10.1177\/1533033818822329","volume":"18","author":"S Funayama","year":"2019","unstructured":"Funayama S, Onishi H, Kuriyama K et al (2019) Renal cancer is not radioresistant: slowly but continuing shrinkage of the tumor after stereotactic body radiation therapy. Technol Cancer Res Treat 18:1533033818822329. https:\/\/doi.org\/10.1177\/1533033818822329","journal-title":"Technol Cancer Res Treat"},{"key":"5140_CR18","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/cncr.31156","volume":"124","author":"S Siva","year":"2018","unstructured":"Siva S, Louie AV, Warner A et al (2018) Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: a report from the International Radiosurgery Oncology Consortium for kidney (IROCK). Cancer 124:934\u2013942. https:\/\/doi.org\/10.1002\/cncr.31156","journal-title":"Cancer"},{"key":"5140_CR19","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.clgc.2018.10.002","volume":"17","author":"AM Saad","year":"2019","unstructured":"Saad AM, Gad MM, Al-Husseini MJ, Ruhban IA, Sonbol MB, Ho TH (2019) Trends in renal-cell carcinoma incidence and mortality in the United States in the last 2 decades: a SEER-based study. Clin Genitourin Cancer 17:46\u201357e5. https:\/\/doi.org\/10.1016\/j.clgc.2018.10.002","journal-title":"Clin Genitourin Cancer"},{"key":"5140_CR20","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jvir.2017.08.013","volume":"29","author":"JR Rivero","year":"2018","unstructured":"Rivero JR, De La Cerda J, Wang H et al (2018) Partial nephrectomy versus termal ablation for clinical stage T1 renal masses: systematic review and meta-analysis of more than 3,900 patients. J Vasc Interv Radiol 29:18\u201329. https:\/\/doi.org\/10.1016\/j.jvir.2017.08.013","journal-title":"J Vasc Interv Radiol"},{"key":"5140_CR21","doi-asserted-by":"publisher","first-page":"e13102","DOI":"10.1097\/MD.0000000000013102","volume":"97","author":"YE Yoon","year":"2018","unstructured":"Yoon YE, Lee HH, Kim KH et al (2018) Focal therapy versus robot-assisted partial nephrectomy in the management of clinical T1 renal masses: a systematic review and meta-analysis. Med (Baltim) 97:e13102. https:\/\/doi.org\/10.1097\/MD.0000000000013102","journal-title":"Med (Baltim)"},{"key":"5140_CR22","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s10585-020-10052-0","volume":"37","author":"CA Helis","year":"2020","unstructured":"Helis CA, Hughes RT, Nieto K, Ufondo A, Daugherty EC, Farris MK (2020) Adrenal SBRT: a multi-institutional review of treatment outcomes and toxicity. Clin Exp Metastasis 37:585\u2013592. https:\/\/doi.org\/10.1007\/s10585-020-10052-0","journal-title":"Clin Exp Metastasis"},{"key":"5140_CR23","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.jvir.2020.12.010","volume":"32","author":"S Pan","year":"2021","unstructured":"Pan S, Baal JD, Chen WC et al (2021) Image-guided percutaneous ablation of adrenal metastases: a meta-analysis of efficacy and safety. J Vasc Interv Radiol 32:527\u2013535e1. https:\/\/doi.org\/10.1016\/j.jvir.2020.12.010","journal-title":"J Vasc Interv Radiol"},{"key":"5140_CR24","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13014-020-1480-0","volume":"15","author":"L K\u00f6nig","year":"2020","unstructured":"K\u00f6nig L, H\u00e4fner MF, Katayama S et al (2020) Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients. Radiat Oncol 15:30. https:\/\/doi.org\/10.1186\/s13014-020-1480-0","journal-title":"Radiat Oncol"},{"key":"5140_CR25","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/COC.0000000000000634","volume":"43","author":"NB Figura","year":"2020","unstructured":"Figura NB, Oliver DE, Mohammadi H et al (2020) Novel dose escalation approaches for stereotactic body radiotherapy to adrenal oligometastases: a single-Institution experience. Am J Clin Oncol 43:107\u2013114. https:\/\/doi.org\/10.1097\/COC.0000000000000634","journal-title":"Am J Clin Oncol"},{"key":"5140_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-022-02793-z","author":"C Onal","year":"2022","unstructured":"Onal C, Hurmuz P, Guler OC et al (2022) The role of stereotactic body radiotherapy in switching systemic therapy for patients with extracranial oligometastatic renal cell carcinoma. Clin Transl Oncol. https:\/\/doi.org\/10.1007\/s12094-022-02793-z","journal-title":"Clin Transl Oncol"},{"key":"5140_CR27","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.ijrobp.2010.11.060","volume":"82","author":"F Casamassima","year":"2012","unstructured":"Casamassima F, Livi L, Masciullo S et al (2012) Stereotactic radiotherapy for adrenal gland metastases: University of Florence Experience. Int J Radiat Oncol Biol Phys 82:919\u2013923. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.11.060","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5140_CR28","doi-asserted-by":"publisher","first-page":"7836","DOI":"10.1038\/s41598-020-64770-2","volume":"10","author":"X Zhao","year":"2020","unstructured":"Zhao X, Zhu1 X, Zhuang H et al (2020) Clinical efficacy of stereotactic body Radiation Therapy (SBRT) for adrenal gland metastases: a multicenter retrospective study from China. Sci Rep 10:7836. https:\/\/doi.org\/10.1038\/s41598-020-64770-2","journal-title":"Sci Rep"},{"key":"5140_CR29","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.eururo.2021.09.016","volume":"81","author":"C Masini","year":"2022","unstructured":"Masini C, Iotti C, De Giorgi U et al (2022) Nivolumab in combination with stereotactic body radiotherapy in pretreated patients with metastatic renal cell carcinoma. Results of the phase II NIVES Study. Eur Urol 81:274\u2013282. https:\/\/doi.org\/10.1016\/j.eururo.2021.09.016","journal-title":"Eur Urol"},{"key":"5140_CR30","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1001\/jamaoncol.2021.2939","volume":"7","author":"S Siva","year":"2021","unstructured":"Siva S, Bressel M, Mai T et al (2021) Single-fraction vs multifraction stereotactic ablative body Radiotherapy for Pulmonary oligometastases (SAFRON II). JAMA Oncol 7:1476\u20131485. https:\/\/doi.org\/10.1001\/jamaoncol.2021.2939","journal-title":"JAMA Oncol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-05140-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-024-05140-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-05140-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T21:17:33Z","timestamp":1735852653000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-024-05140-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5140"],"URL":"https:\/\/doi.org\/10.1007\/s00345-024-05140-9","relation":{},"ISSN":["1433-8726"],"issn-type":[{"type":"electronic","value":"1433-8726"}],"subject":[],"published":{"date-parts":[[2024,7,24]]},"assertion":[{"value":"12 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients have given the Informed Consent for being treated and for the clinical and scientific use of their data (CLF 007).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of GENESISCARE Clinical Leader Forum.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional Review Board Statement"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"435"}}